Eli Lilly and Company

As of June 30, 2026, Eli Lilly and Company carries a market capitalization of 864.75B, placing it among publicly traded companies globally. Its enterprise value stands at 901.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eli Lilly and Company's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Eli Lilly and Company has 891.50M shares outstanding.

As of June 30, 2026, Eli Lilly and Company trades at a trailing price-to-earnings ratio of 40.18. The price-to-sales ratio is 13.47, and the price-to-book ratio stands at 31.60.

As of June 30, 2026, Eli Lilly and Company trades at an EV/EBITDA multiple of 31.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Eli Lilly and Company trades at an EV/FCF ratio of 81.47, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 901.88B versus a market cap of 864.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Eli Lilly and Company maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.07, indicating elevated leverage, while an interest coverage ratio of 198.95 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Eli Lilly and Company posted a return on equity (ROE) of 102.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 34.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.53, useful for judging operating efficiency across full business cycles. The company generates approximately 1.31M in revenue per employee across its workforce of 49,250.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.95 indicates how many times Eli Lilly and Company sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Eli Lilly and Company recorded 5.56B in income tax expense. That works out to an effective tax rate of 20.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 27.14B, leaving 21.58B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 21, 2026, Eli Lilly and Company's stock has gained approximately 60.50% over the past 52 weeks. The 50-day moving average sits at 875.90, while the 200-day moving average is 694.74.

Over the twelve months ended June 30, 2026, Eli Lilly and Company generated 64.36B in revenue and converted that into 21.58B in net income, yielding earnings per share of 24.07. EBITDA reached 28.87B, while operating income came in at 32.00B.

As of June 30, 2026, Eli Lilly and Company holds 7.23B in cash and equivalents against 44.36B in total debt, resulting in a net debt position of 37.13B. Total book value stands at 27.37B, with working capital of 13.68B providing operational flexibility.

Eli Lilly and Company produced 22.69B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.73B in capital expenditures, free cash flow totaled 10.95B - equivalent to 12.25 per share.

Over the twelve months ended June 30, 2026, Eli Lilly and Company posted a gross margin of 83.40, reflecting its pricing power and cost economics. The operating margin of 49.72 and net profit margin of 33.53 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Eli Lilly and Company paid dividends of 5.23 per share. The dividend payout ratio of 21.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.26, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.24, meaning Eli Lilly and Company raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Eli Lilly and Company's most recent stock split took place on October 16, 1997 with a 1:2 split ratio.

As of June 30, 2026, Eli Lilly and Company has an Altman Z-Score of 8.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.